Current Status
Not Enrolled
Price
Free
Get Started

What is the current evidence on lung cancer screening?

How can risk prediction and biomarkers contribute to make lung cancer screening more effective and efficient?

What role could artificial intelligence play in lung cancer screening?

6 December 2022, 14:00 CET

Register now!

Join us for the live event, ask your questions, and share your comments directly with our speakers.

Share this learning opportunity

SPEAKERS

LUNG CANCER SCREENING: WHERE DO WE STAND?

Professor Joachim Aerts

Head, Department of Pulmonary Medicine

Erasmus University Medical Center, Netherlands

There is a lot of debate about the efficacy of lung cancer screening. This presentation will discuss the latest state of affairs of the published data on lung cancer screening

THE FUTURE OF LUNG CANCER SCREENING: RISK PREDICTION, BIOMARKERS, AND ARTIFICIAL INTELLIGENCE

Dr Hilary Robbins

Scientist, Genomic Epidemiology Branch

International Agency for Research on Cancer, Lyon, France

Lung cancer screening programmes can be made more effective and efficient by using information about individual risk to tailor aspects of eligibility, screening frequency, and nodule follow-up. This presentation will discuss research developments in predicting lung cancer occurrence using statistical models, blood-based biomarkers, and artificial intelligence with low-dose computed tomography (CT) images.

CHAIR

Dr Rosa Giuliani

Consultant in Medical Oncology, Clatterbridge Cancer Centre, United Kingdom

Director of Public Policy, European Society for Medical Oncology (ESMO)

Organized with the support of and in collaboration with the European Society for Medical Oncology (ESMO).

Scroll to Top